- 专利标题: Tumor-specific adenovirus vectors and therapeutic uses
-
申请号: US15771110申请日: 2016-10-28
-
公开(公告)号: US11246896B2公开(公告)日: 2022-02-15
- 发明人: Michael Lan , Mary Breslin
- 申请人: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- 申请人地址: US LA Baton Rouge
- 专利权人: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- 当前专利权人: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- 当前专利权人地址: US LA Baton Rouge
- 代理机构: Baker Donelson
- 国际申请: PCT/US2016/059382 WO 20161028
- 国际公布: WO2017/075395 WO 20170504
- 主分类号: C12N15/86
- IPC分类号: C12N15/86 ; A61K35/761 ; A61K49/00 ; G01N33/50 ; A61P35/00 ; C12Q1/6886
摘要:
A conditionally replicating adenovirus were generated that can specifically replicate and express therapeutic genes in neuroendocrine tumors. The promoter-specific expression of the adenoviruses is regulated upstream by an INSM1 (insulinoma-associated-1) promoter that is silent in normal adult tissues but active in developing neuroendocrine cells and neuroendocrine tumors. By placing the I NSM 1-promoter with an insulator and two copies of neuronal restrictive silencer elements in an adenoviral vector, the construct can retain tumor specificity and drive expression of a mutated adenovirus E1A gene (Δ24E1A) and the herpes simplex virus thymidine kinase gene. The I NSM1-promoter-driven viruses could replicate specifically in the I NSM1-positive cells and I NSM1-specific HSV-tk expression in combination with ganciclovir treatment displayed dose-dependent tumor cell-specific killing in insulinomas. When the INSM1-promoter driven HSV-tk was combined with Δ24E1A and I NSM 1 p-HSV-tk viruses, the co-infected insulinoma expressed higher levels of HSV-tk and more efficient tumor suppression as compared to the I NSM1 p-HSV-tk virus alone.
公开/授权文献
- US20190247452A1 TUMOR-SPECIFIC ADENOVIRUS VECTORS AND THERAPEUTIC USES 公开/授权日:2019-08-15
信息查询
IPC分类: